

DOCKET NO.: 283625US0PCT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF:

GROUP: 1627

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,402

EXAMINER: RAMACHANDRAN,  
UMAMAHESWARI

FILED: July 5, 2006

FOR: ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND  
WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6  
RECEPTOR AFFINITY

**RESTRICTION RESPONSE**

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

Sir:

In response to the Restriction Requirement dated December 02, 2009, Applicants provisionally elect the following species, for examination purposes only:

(1) 2-(4-(8-methyl-2-oxo-2,4-dihydro-1H-benzo[d][1,3]oxazin-1-yl)piperidin-1-yl) N-(9-oxo-9H-fluoren-3-yl)acetamide hydrochloride as a compound binding NPY5 receptor (at least claims 1 - 45 readable thereon);

(2) 5-chloro-N-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)naphthalene-2-sulfonamide as a compound binding 5-HT6 receptor (at least claims 1 - 45 readable thereon);  
and

(3) regulation of appetite as the disease (at least claims 7, 9 and 34 - 45 readable thereon).

**Remarks/Arguments** begin on page 2 of this paper.